Olin Corporation enters the back half of June with short sellers adding pressure, options traders at their most defensive in a year, and a stock that has shed 11% over the past month — yet the Street's collective response is muted rather than alarmed.
The short positioning is the clearest story this week. Shorts rebuilt aggressively from June 8, jumping from roughly 10.5 million shares to 14.4 million by June 16 — a 37% weekly surge that pushed short interest to 12.6% of free float. That level is high enough to reflect genuine conviction, not noise. FINRA's most recent fortnightly data corroborates the direction: 13.5 million shares short with 7.04 days-to-cover, a figure that would make any meaningful unwind slow and painful. The ORTEX short score has tracked the move, climbing from 50 on June 2 to 57.7 now — a near eight-point swing that confirms the shift is real. Borrow cost has doubled over the past week to 0.45%, though in absolute terms it remains low. Availability is ample at 766% — there is no mechanical squeeze pressure in the lending pool — so this is a story of bears adding exposure, not trapped longs being squeezed out.
Options reinforce the bearish lean. The put/call ratio has risen to 0.70, the highest print of the past 52 weeks, running 2.6 standard deviations above its 20-day average of 0.66. That is an unusual degree of skew for a stock in this sector. The setup has tightened since earlier this month, when the PCR hovered closer to 0.67-0.68. Combined with the short interest rebuild, it points to a market that is actively positioning for further downside rather than fading the decline.
The Street is unconvinced that the bears are wrong — but not fully in agreement either. Goldman Sachs, JP Morgan, and UBS all raised price targets in mid-May, yet all three kept neutral ratings. Morgan Stanley sits at Underweight with a $22 target, already below the current $23.81 close. The consensus target of roughly $29.50 implies modest upside from current levels, but the path there is contested. Bears point to input cost pressure across Winchester and CAPV, uncertain chlorine demand, and limited pricing visibility. Bulls lean on the expectation of improved Q2 volumes, cost management discipline, and a resolution of the Freeport facility outage. Factor scores shade bearish: EV/EBIT ranks in the first percentile of the universe, and the short score rank is in the fifth — both signals that the valuation and short-side pressure remain extreme relative to peers. EPS surprise, by contrast, ranks in the 91st percentile, which means the company has historically found ways to beat a low bar.
Peer context adds nuance. HUN fell 17% on Tuesday and is down 9% on the week — a sharper move than OLN's 5.9% single-day drop. TROX gained 7% on the week despite Tuesday weakness. WLK is roughly flat on the week, as is DOW. OLN's underperformance is therefore not purely sector-driven; the stock is carrying incremental negative weight from its own short rebuilding and structural earnings uncertainty.
Q3 earnings are flagged for July 30. That print — and what management says about chlor-alkali pricing and Winchester volume trends — is where the current positioning will either be vindicated or reversed.
See the live data behind this article on ORTEX.
Open OLN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
